Economics-Reference-Cited by-同舟云学术

Economics

Published:2016-01 Issue:S2 Volume:16 Page:169-194
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:American Journal of Transplantation

Author:

Schnitzler M. A.¹²,Valapour M.²³,Skeans M. A.²,Axelrod D. A.⁴,Lentine K. L.¹,Randall H. B.⁵,Snyder J. J.²⁶,Israni A. K.²⁶⁷,Kasiske B. L.²⁷

Affiliation:

1. Center for Outcomes Research; Saint Louis University School of Medicine; St. Louis MO

2. Scientific Registry of Transplant Recipients; Minneapolis Medical Research Foundation; Minneapolis MN

3. Department of Pulmonary Medicine; Respiratory Institute; Cleveland Clinic; Cleveland OH

4. Section of Transplant Surgery; Dartmouth-Hitchcock Medical Center; Lebanon NH

5. Division of Abdominal Transplant; Saint Louis University School of Medicine; St. Louis MO

6. Department of Epidemiology and Community Health; University of Minnesota; Minneapolis MN

7. Department of Medicine; Hennepin County Medical Center; University of Minnesota; Minneapolis MN

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Reference6 articles.

1. Ivacaftor: A novel gene-based therapeutic approach for cystic fibrosis;Condren;J Pediatr Pharmacol Ther,2013

2. Ferreira LM. Two new IPF treatments reportedly will cost between $94K and $96K a year. Pulmonary Fibrosis News Today 2014 http://pulmonaryfibrosisnews.com/2014/10/23/two-new-ipf-treatments-reportedly-will-cost-94k-96k-year/

3. Boehrenger price list http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Compliance+-+Marketing+and+Sales/States/Vermont/Ofev/OFEV+Vermont+Long+Form+Disclosure.pdf

4. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR;Wainwright;N Engl J Med,2015

5. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis;Richeldi;N Engl J Med,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Costs of End-of-Life Hospitalizations in the United States for People With Pulmonary Diseases;CHEST;2024-07

2. Modeling the economic benefit of targeted mild hypothermia in deceased donor kidney transplantation;Clinical Transplantation;2019-07

3. Regulatory Environment and Finances of Running a Pediatric Transplant Program;Solid Organ Transplantation in Infants and Children;2018

4. Regulatory Environment and Finances of Running a Pediatric Transplant Program;Solid Organ Transplantation in Infants and Children;2016